Showing results (2091-2100 of 5,939) with videos related to

Sort By:
Pageof 594
The Prostate|August 22, 2019
A three-gene DNA methylation biomarker accurately classifies early stage prostate cancerPalak G Patel, Thomas Wessel, Atsunari Kawashima, et al.
The Prostate|September 10, 2019
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
The Prostate|September 11, 2019
Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancerJordan E Vellky, Tyler M Bauman, Emily A Ricke, et al.
The Prostate|October 23, 2018
A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growthShu-Han Yu, Janielle P Maynard, Ajay M Vaghasia, et al.
The Prostate|December 14, 2021
Metabolic syndrome and prostate cancer in Afro-Caribbean menFlorian Lefebvre, Anne Blanchet-Deverly, Leah Michineau, et al.
The Prostate|December 20, 2021
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology AssociationMurat Yavuz Koparal, Tevfik Sinan Sözen, Nejdet Karşıyakalı, et al.
The Prostate|November 4, 2021
Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systemsJulian Hanske, Yannic Risse, Florian Roghmann, et al.
The Prostate|July 24, 2019
An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progressionYoshiyuki Miyazawa, Yoshitaka Sekine, Nobuaki Shimizu, et al.
The Prostate|March 12, 2014
Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cellsTakashi Hamakawa, Shoichi Sasaki, Yasuhiro Shibata, et al.
The Prostate|March 12, 2014
Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targetingLynn N Thomas, Jennifer Merrimen, David G Bell, et al.
Pageof 594